On August 7th, Novo Nordisk released its 2024 H1 financial report. Its star product GLP-1 (glucagon like peptide-1) drug semaglutide sold for $13 billion and is expected to challenge the global drug king in 2024.
Oral version of semaglutide research results revealed, with a weight loss of 13.6% in one year
2024-11-13 11:12:13 Source：